HK1081975A1 - Dimerized peptide - Google Patents

Dimerized peptide

Info

Publication number
HK1081975A1
HK1081975A1 HK06102442.4A HK06102442A HK1081975A1 HK 1081975 A1 HK1081975 A1 HK 1081975A1 HK 06102442 A HK06102442 A HK 06102442A HK 1081975 A1 HK1081975 A1 HK 1081975A1
Authority
HK
Hong Kong
Prior art keywords
peptide
tumor antigen
dimerized peptide
antigen peptide
dimerized
Prior art date
Application number
HK06102442.4A
Other languages
English (en)
Inventor
Hideo Takasu
Fumio Samizo
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Chugai Pharmaceutical Co Ltd
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc, Chugai Pharmaceutical Co Ltd, Dainippon Sumitomo Pharma Co filed Critical Int Inst Cancer Immunology Inc
Publication of HK1081975A1 publication Critical patent/HK1081975A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK06102442.4A 2003-01-15 2006-02-23 Dimerized peptide HK1081975A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003007122 2003-01-15
PCT/JP2004/000254 WO2004063217A1 (ja) 2003-01-15 2004-01-15 二量体化ペプチド

Publications (1)

Publication Number Publication Date
HK1081975A1 true HK1081975A1 (en) 2006-05-26

Family

ID=32709100

Family Applications (2)

Application Number Title Priority Date Filing Date
HK06102442.4A HK1081975A1 (en) 2003-01-15 2006-02-23 Dimerized peptide
HK10107803.0A HK1141539A1 (en) 2003-01-15 2010-08-16 Dimerized peptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK10107803.0A HK1141539A1 (en) 2003-01-15 2010-08-16 Dimerized peptide

Country Status (13)

Country Link
US (2) US20060217297A1 (de)
EP (2) EP1584627B1 (de)
JP (2) JP4498274B2 (de)
KR (2) KR101399678B1 (de)
CN (2) CN1756763B (de)
AT (1) ATE444969T1 (de)
AU (1) AU2004204031B2 (de)
BR (1) BRPI0406800B8 (de)
CA (1) CA2513701C (de)
DE (1) DE602004023476D1 (de)
ES (1) ES2332590T3 (de)
HK (2) HK1081975A1 (de)
WO (1) WO2004063217A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1103564T3 (da) * 1998-07-31 2009-05-11 Int Inst Cancer Immunology Inc Cancerantigener baseret på tumorsuppressorgen WT1-produkt
JP3728439B2 (ja) * 2001-03-22 2005-12-21 治夫 杉山 Wt1改変ペプチド
CA2448109A1 (en) * 2001-05-25 2002-12-05 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
AU2003262094A1 (en) * 2002-09-12 2004-04-30 Haruo Sugiyama Cancer antigen peptide preparation
CN101580538B (zh) 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
PL1731605T3 (pl) * 2004-03-31 2010-08-31 Int Inst Cancer Immunology Inc Nowotworowe peptydy antygenowe pochodzące z WT1
RU2396088C2 (ru) * 2005-02-04 2010-08-10 СУРВАК АпС Вакцина на основе пептидов сурвивина
BRPI0619255B8 (pt) * 2005-11-30 2021-05-25 Chugai Seiyaku Kabishiki Kaisha composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer
DK1988163T3 (da) * 2006-02-22 2012-08-20 Int Inst Cancer Immunology Inc Hla-a*3303-begrænset wt1 peptid og farmaceutisk sammensætning omfattende det samme
CA2641909A1 (en) * 2006-02-23 2007-08-30 Fibrex Medical Research & Development Gmbh Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2008081701A1 (ja) 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Hla-a*1101拘束性wt1ペプチド、およびそれを含む医薬組成物
DK2119778T3 (en) 2007-02-27 2016-01-25 Int Inst Cancer Immunology Inc A process for the activation of the helper T cell, and composition for use in this process
CN101896499B (zh) * 2007-08-30 2014-02-12 库尔Dm股份有限公司 使用前胰岛肽及其类似物的组合物和方法
AU2011313327B2 (en) 2010-10-05 2015-10-22 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
EP2646459B1 (de) * 2010-12-02 2020-01-08 Bionor Immuno AS Peptidgerüstentwurf
JP5893640B2 (ja) * 2010-12-23 2016-03-23 ファルネファ オーストリア ゲーエムベーハー Oprf/i試薬と入院および他の患者におけるその利用
EP3338798A1 (de) 2011-01-06 2018-06-27 Bionor Immuno AS Multimere peptide
WO2012105224A1 (ja) * 2011-01-31 2012-08-09 オリンパス株式会社 ワクチン・アジュバント
WO2014007266A1 (ja) 2012-07-02 2014-01-09 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
TWI646970B (zh) 2012-12-17 2019-01-11 大塚製藥股份有限公司 活化輔助t細胞的方法
JP6294868B2 (ja) 2013-03-12 2018-03-14 大日本住友製薬株式会社 液体水性組成物
US10588952B2 (en) 2013-03-29 2020-03-17 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of ERAP1
DK2982681T3 (en) * 2013-03-29 2018-12-10 Sumitomo Dainippon Pharma Co Ltd WT1 ANTIGENPEPTIDKONJUGATVACCINE
JP2016539922A (ja) 2013-10-17 2016-12-22 ソウル ナショナル ユニバーシティ アールアンドディービー ファウンデーション 細胞透過性αヘリックスペプチド多量体、これの製造方法およびその用途
EP3199175B1 (de) * 2014-09-27 2022-03-23 Sumitomo Dainippon Pharma Co., Ltd. Pharmazeutische zusammensetzung zur injektion
JP6671141B2 (ja) * 2014-10-21 2020-03-25 大日本住友製薬株式会社 懸濁液剤
JP6515182B2 (ja) * 2015-05-20 2019-05-15 大日本住友製薬株式会社 Wt1抗原ペプチドおよび免疫調節剤の併用
WO2017009846A1 (en) * 2015-07-14 2017-01-19 Yeda Research And Development Co. Ltd. Peptide combinations for use in the diagnosis of schizophrenia
US20200368338A1 (en) * 2017-12-27 2020-11-26 Sumitomo Dainippon Pharma Co., Ltd. Conjugate of wt1-derived peptides and composition comprising the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5779696A (en) * 1995-06-01 1996-12-18 Kishimoto, Tadamitsu Leukemic cell growth inhibitor containing antisense oligonuc leotide derivative against wilms' tumor gene (wt1)
JP3060287B2 (ja) 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
DK1103564T3 (da) 1998-07-31 2009-05-11 Int Inst Cancer Immunology Inc Cancerantigener baseret på tumorsuppressorgen WT1-produkt
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
ES2310052T3 (es) * 1998-09-30 2008-12-16 Corixa Corporation Composiciones y metodos para la inmunoterapia especifica de wt1.
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
US20050050580A1 (en) 2000-12-13 2005-03-03 Masashi Gotoh Transgenic animal expressing hla-a24 and utilization thereof
JP3728439B2 (ja) 2001-03-22 2005-12-21 治夫 杉山 Wt1改変ペプチド
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003028757A1 (fr) * 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
CN100408683C (zh) * 2002-06-12 2008-08-06 株式会社国际癌症免疫研究所 Hla-a24限制性癌抗原肽
CN101580538B (zh) 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
PL1731605T3 (pl) 2004-03-31 2010-08-31 Int Inst Cancer Immunology Inc Nowotworowe peptydy antygenowe pochodzące z WT1

Also Published As

Publication number Publication date
EP1584627A4 (de) 2006-03-15
JP4498274B2 (ja) 2010-07-07
EP2154145B1 (de) 2013-04-24
CA2513701C (en) 2013-06-18
CN1756763A (zh) 2006-04-05
DE602004023476D1 (de) 2009-11-19
US20100292164A1 (en) 2010-11-18
EP1584627B1 (de) 2009-10-07
CN101851275A (zh) 2010-10-06
KR20120054644A (ko) 2012-05-30
AU2004204031B2 (en) 2010-03-04
KR101399678B1 (ko) 2014-05-27
KR20050098863A (ko) 2005-10-12
EP2154145A2 (de) 2010-02-17
EP1584627A1 (de) 2005-10-12
ATE444969T1 (de) 2009-10-15
JPWO2004063217A1 (ja) 2006-06-01
EP2154145A3 (de) 2010-05-19
US8242084B2 (en) 2012-08-14
CA2513701A1 (en) 2004-07-29
US20060217297A1 (en) 2006-09-28
BRPI0406800A8 (pt) 2016-11-01
BRPI0406800A (pt) 2006-01-17
BRPI0406800B8 (pt) 2021-05-25
CN1756763B (zh) 2010-05-26
HK1141539A1 (en) 2010-11-12
AU2004204031A1 (en) 2004-07-29
JP4926231B2 (ja) 2012-05-09
WO2004063217A1 (ja) 2004-07-29
JP2010047603A (ja) 2010-03-04
ES2332590T3 (es) 2010-02-09
BRPI0406800B1 (pt) 2020-08-11

Similar Documents

Publication Publication Date Title
HK1141539A1 (en) Dimerized peptide
WO2003102157A3 (en) Synthetic antibody phage libraries
WO2007064919A3 (en) Binding polypeptides with restricted diversity sequences
WO2005012531A3 (en) Antibody cdr polypeptide sequences with restricted diversity
HK1079979A1 (de)
ATE542137T1 (de) Immunocytokine mit modulierter selektivität
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
HK1071898A1 (en) Recombinant antibodies, and compositions and methods for making and using the same
RS51180B (sr) Interleukin-10 antitela
IL142025A0 (en) Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds
CY1113850T1 (el) Νεα παραγωγα ινσουλινης
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
GB0121591D0 (en) Hybrid and tandem expression of neisserial proteins
WO2004065416A3 (en) Synthetic antibody phage libraries
ZA200708407B (en) IL-21 variants
EP1983059A3 (de) Reaktionsgemische zur Herstellung von Dipeptiden
AU2003230603A1 (en) Controlled modulation of amino acid side chain length of peptide antigens
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
EP1550453A4 (de) Krebs-antigen-peptid-praparat
WO2003074546A8 (de) Streptavidin-bindungspeptid
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
WO2005037236A3 (en) Novel heat shock protein 20-related polypeptides and uses therefor
ATE467421T1 (de) Cytokine und cytokinrezeptoren mit reduzierter immunogenität
GB0220805D0 (en) Peptide monomers and protein structures

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240114